undefined undefined
NaN.000
NaN.00%
Zentalis Pharmaceuticals announced positive survival data from the DENALI Part 1b trial for azenosertib, a potential first-in-class oral therapy for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI Part 2c enrollment is expected to complete in November 2026, with a topline readout anticipated in the first half of 2027. The company reported $228.9 million in cash as of September 30, 2026, providing runway into the first half of ...
11-09 21:05
Spencer’s Retail Ltd. ( ($IN:SPENCERS) ) has issued an announcement. Spencer’s ...
11-05 21:57
Spencer’s Retail Ltd. ( ($IN:SPENCERS) ) just unveiled an update. Spencer’s Ret...
11-05 21:57
Zentalis Pharmaceuticals announced interim OS data from the DENALI Part 1b study for azenosertib in platinum-resistant ovarian cancer (PROC). Cyclin E1-positive patients (n=48) had a median OS of 15.8 months, compared to 7.5 months in Cyclin E1-negative patients (n=46). No new safety signals were observed. The data will be presented at the ESMO Congress 2026 on October 23. Azenosertib is being further developed in DENALI Part 2 and the ASPENOVA P...
10-18 22:05
Spencer’s Retail Ltd. ( ($IN:SPENCERS) ) has issued an announcement. Spencer’s ...
10-04 22:52
ALX Oncology press release (ALXO): Q2 GAAP EPS of -$0.13. Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of June 30, 2026, were $153.4 million. The Company believes ...
08-06 20:14
• Insmed shares rose following positive clinical trial data and potential acquisition interest. • Analysts revised revenue models, setting an average price target of $196.74. • Technical indicators show a sell signal with the stock currently in oversold territory.
08-06 19:15